Should You Get a Stem Cell Transplant for Multiple Myeloma? Should multiple myeloma patients undergo an autologous stem cell transplant immediately after induction therapy? Learn the benefits, risks, survival data, and expert opinions on early versus delayed ASCT.
What Is the Current Evidence on ASCT?
Studies consistently show:
- Early ASCT improves progression-free survival (PFS)
- Early ASCT has not consistently improved overall survival (OS)
- Many patients can safely collect stem cells and delay transplant until relapse
- Modern quadruplet therapies have changed the transplant discussion considerably
I guess that if you are reading this post, you have been diagnosed with multiple myeloma and your oncologist is urging you to have a stem cell transplant immediately following your induction chemotherapy.
But you are wondering if it is better to transplant or not to transplant? And if you can harvest your stem cells and then wait?
An Autologous Stem Cell Transplant (ASCT) can be a tempting therapy option. Your oncologist tells you that an ASCT is the “best option.” You feel as though it might be best to get it over with. Sure, an ASCT will be tough but then I will be in remission for years…
My Experience: I underwent an autologous stem cell transplant shortly after diagnosis. My remission lasted only 10 months. Although ASCT did not provide long-term disease control for me personally, the experience taught me the importance of understanding all available treatment options.
So how am I writing this blog post? I am a long-term MM survivor and MM cancer coach. As the article linked below discusses, MM is a complicated blood cancer. Even MM specialists disagree on the “best option” for MMers.
New Myeloma Therapies Are Changing the Transplant Decision
As a MM survivor who endured conventional standard-of-care MM therapies in the 90s, I am amazed at how the therapies below have changed the life of a newly diagnosed MM patient.
- Daratumumab
- CAR-T therapy
- Bispecific antibodies
- MRD-guided treatment decisions
Can You Delay a Stem Cell Transplant in Multiple Myeloma?
Yes. Many patients with multiple myeloma collect stem cells after induction therapy and store them for future use. Clinical studies show that early ASCT improves progression-free survival, but overall survival differences remain less clear. For some patients, delaying transplant until the first relapse is a reasonable option.
ASCT Early/Delayed Pros and Cons
| Early ASCT |
Delayed ASCT |
| Longer progression-free survival |
Preserves quality of life |
| Deeper remission |
Avoids immediate toxicity |
| Higher MRD-negative rates |
Uses modern therapies longer |
| More intensive treatment upfront |
Keeps transplant available later |
| Greater short-term side effects |
Risk disease may progress before transplant |
As MM specialists go, Dr. Berenson is one of the best. He has the best average survival statistics of any MM specialist that I know of. While the long and growing list of FDA-approved MM therapies should give MMers hope for their long-term survival, I have remained in complete remission since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle.
I believe that the newly diagnosed MMer’s “best option” will be able to manage their MM with the best of both conventional and non-conventional MM therapies.
Whether you are debating treatment options, currently undergoing treatment and experiencing painful side effects, or trying to figure out how to stay in remission, I want to share what I’ve learned from 22 years of full remission from Multiple Myeloma.
Learn about what integrative therapies are and how you can use them to optimize the efficacy of your specific chemotherapy while healing short term and long term side effects.
If you have a question or comment about MM scroll down the page, write a post and I will reply to you ASAP.
Frequently Asked Questions
Is stem cell transplant still standard treatment for multiple myeloma?
Yes. ASCT remains a standard treatment option for eligible patients, although experts continue to debate the optimal timing.
Can I collect stem cells and wait?
Yes. Many patients harvest stem cells after induction therapy and reserve them for future use if relapse occurs.
Does ASCT cure multiple myeloma?
No. ASCT is not considered curative but can deepen remission and prolong disease control.
What are the major side effects of ASCT?
Common side effects include fatigue, infections, low blood counts, gastrointestinal symptoms, and temporary reductions in quality of life.
David Emerson
Authority Links
To learn more about multiple myeloma
Beware of Financial Toxicity in Multiple Myeloma
The 7 Most Popular Myeloma Blog Posts on PeopleBeatingCancer:
- Multiple Myeloma- Tom Brokaw, Celebrities, Survivor Stories
- Multiple Myeloma Diet
- The Multiple Myeloma Coaching Course
- Myeloma and Fenbendazole?
- Antineoplastons, Burzynski, Myeloma and Me
- Top Myeloma Hospitals, Specialists-
- Myeloma Survivor- A Different Kind of Second Opinion
Recommended Reading:
“There is a profound disagreement over whether early stem cell transplant (SCT) should still be characterized as a standard early intervention for multiple myeloma (MM), even in relatively young patients…
“The treatment of multiple myeloma is no longer a 100-yard dash; it is a marathon,” According to Dr. Berenson, better-tolerated, newer drug therapies now produce response rates that rival those produced with SCT, while preserving future options when the cancer progresses…
“Patients need to be able to avail themselves of the opportunity to seek the newer therapies. Reducing that ability with too much prior treatment at too high of a dose is detrimental to their long-term outcomes, which not only includes their overall survival but their quality of life,” Dr. Berenson said…
“Conclusion
After nearly 3 decades of debate and several randomized phase 3 trials, it is clear that ASCT as a treatment modality has stood the test of time. It continues to be an effective modality to provide durable disease control for myeloma even with the introduction of novel agents.
Given the depth of response and the PFS advantage seen in phase 3 trials, ASCT should be considered as part of the initial therapy.
However, without a clear OS advantage to early ASCT based on the data available today, a delayed ASCT is a reasonable approach should the patient and the treating physician desire to pursue that approach after a thorough discussion of the pros and cons of either approach, as discussed in this article…”
